Functionalized gold nanoparticles for the binding, stabilization, and delivery of therapeutic DNA, RNA, and other biological macromolecules

por DeLong, Robert K, Reynolds, Christopher M, Malcolm, Yaneika, Schaeffer, Ashley, Severs, Tiffany, Wanekaya, Adam
Publicado em 2010

Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cel...

por Durie, Brian G M, Hoering, Antje, Abidi, Muneer H, Rajkumar, S Vincent, Epstein, Joshua, Kahanic, Stephen P, Thakuri, Mohan, Reu, Frederic, Reynolds, Christopher M, Sexton, Rachael, Orlowski, Robert Z, Barlogie, Bart, Dispenzieri, Angela
Publicado no Lancet (2016)

Longer term follow-up of the randomized phase III trial SWOG S0777: bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (Pts) with previously...

por Durie, Brian G. M., Hoering, Antje, Sexton, Rachael, Abidi, Muneer H., Epstein, Joshua, Rajkumar, S. Vincent, Dispenzieri, Angela, Kahanic, Stephen P., Thakuri, Mohan C., Reu, Frederic J., Reynolds, Christopher M., Orlowski, Robert Z., Barlogie, Bart
Publicado no Blood Cancer J (2020)